



**FREE BETA-SUBUNIT OF HUMAN CHORIONIC
GONADOTROPIN (Free β -hCG)
ENZYME IMMUNOASSAY TEST KIT**

**Enzyme Immunoassay for the quantitative determination
of Free Beta-Subunit of Human Chorionic Gonadotropin
(Free β -hCG) in Human Serum**

For In-Vitro and professional use only

Store at 2 to 8°C.

INTRODUCTION

Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone normally produced by placenta during pregnancy. The hormone is present in blood and urine around seven to thirteen days following implantation of the fertilized ovum. Structurally intact hCG molecules consist of two non-covalently linked polypeptide subunits, the alpha and beta chain subunits. Measurement of intact hCG and of the alpha subunit of hCG appears to give similar results in blood and urine but not the levels of beta subunit. In the normal second-trimester maternal sera, the level of intact hCG range from 20,000 mIU/ml to 50,000 mIU/ml (1 ng = 15 mIU). In contrast, the levels of either free α - or free β -hCG are on average one half of 1% of hCG levels. hCG and the free subunits appear not to be useful as serological markers for nontrophoblastic tumors; however, the absolute increase of β -hCG level in choriocarcinoma patients clearly differentiates it from normal pregnancy.

Recent studies showed a significant increase in the level of free β -hCG subunit in trisomy cases as compared with controls. Hence, it has been suggested that free β -hCG subunit assay in a combination of maternal serum AFP could be effective in a screening protocol for trisomy.

PRINCIPLE OF THE TEST

The free β -hCG ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a unique monoclonal antibody directed against a distinct antigenic determinant on the β -subunit of the hCG molecule. Mouse monoclonal anti- β -hCG antibody is used for solid phase immobilization (on the microtiter wells). A rabbit anti- β -hCG antibody is in the antibody-enzyme (horseradish peroxidase) conjugate solution. The test sample is allowed to react sequentially with the two antibodies, resulting in the β -hCG molecules being sandwiched between the solid phase and enzyme-linked antibodies. After incubation two separate 30 minute incubations at 37 °C, the wells are washed with water to remove unbound labeled antibodies. A solution of TMB Reagent is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution changing the color to yellow. The concentration of β -hCG is directly proportional to the color intensity of the test sample. Absorbance is measured spectro-photometrically at 450 nm.

REAGENTS

Materials provided with the kit:

- Murine Monoclonal Anti β -hCG-coated microtiter wells.
- Set of Reference Standards: 0, 2.5, 5, 10, 25, and 50 ng/ml, lyophilized.
- Zero Buffer (Sample diluent), 13 ml.
- Enzyme Conjugate Reagent, 18 ml.
- TMB Reagent (One-Step), 11 ml.

- Stop Solution (1N HCl), 11 ml.

Materials required but not provided:

- Precision pipettes: 50 μ l, 100 μ l, 150 μ l, and 1.0 ml.
- Disposable pipette tips.
- Distilled water.
- Vortex mixer or equivalent.
- Absorbent paper or paper towel.
- Graph paper.
- Microtiter plate reader.

SPECIMEN COLLECTION AND PREPARATION

Serum should be prepared from a whole blood specimen obtained by acceptable medical techniques. This kit is for use with serum samples without additives only.

**STORAGE OF TEST KIT AND
INSTRUMENTATION**

Unopened test kits should be stored at 2-8 °C upon receipt and the microtiter plate should be kept in a sealed bag with desiccants to minimize exposure to damp air. Opened test kits will remain stable until the expiration date shown, provided it is stored as described above. A microtiter plate reader with a bandwidth of 10 nm or less and an optical density range of 0-2 OD or greater at 450 nm wavelength is acceptable for use in absorbance measurement.

REAGENT PREPARATION

1. All reagents should be brought to room temperature (18-25 °C) before use.
2. Reconstitute each lyophilized standard with 1.0 ml distilled water. Allow the reconstituted material to stand for at least 20 minutes and mix gently. Reconstituted standards will be stable for up to 30 days when stored sealed at 2-8 °C.

ASSAY PROCEDURE

1. Secure the desired number of coated wells in the holder.
2. Dispense 50 μ l of standards, specimens, and controls into appropriate wells.
3. Dispense 100 μ l of Zero Buffer into each well.
4. Thoroughly mix for 30 seconds. It is very important to mix them completely.
5. Incubate at 37 °C for 30 minutes.
6. Remove the incubation mixture by flicking plate contents into a sink.
7. Rinse and flick the microtiter wells 5 times with distilled or deionized water. (Please do not use tap water.)
8. Strike the wells sharply onto absorbent paper or paper towels to remove all residual water droplets.
8. Dispense 150 μ l of Enzyme Conjugate Reagent into each well. Gently mix for 10 seconds.
9. Incubate at 37 °C for 30 minutes.
10. Remove the incubation mixture by flicking plate contents into a waste container.
11. Rinse and flick the microtiter wells 5 times with distilled or deionized water. (Please do not use tap water.)
12. Strike the wells sharply onto absorbent paper or paper towels to remove all residual water droplets.
13. Dispense 100 μ l of TMB Reagent into each well. Gently mix for 10 seconds.
14. Incubate at room temperature for 20 minutes.
15. Stop the reaction by adding 100 μ l of Stop Solution to each well.
16. Gently mix for 30 seconds. **It is important to make sure that all the blue color changes to yellow color completely.**
17. Read optical density at 450 nm with a microtiter well reader **within 15 minutes.**


CALCULATION OF RESULTS

1. Calculate the mean absorbance value (A_{450}) for each set of reference standards, controls and patient samples.
2. Construct a standard curve by plotting the mean absorbance obtained from each reference standard against its concentration in ng/ml on graph paper, with absorbance values on the vertical or Y axis, and concentrations on the horizontal or X axis.
3. Use the mean absorbance values for each specimen to determine the corresponding concentration of β -hCG in ng/ml from the standard curve.

EXAMPLE OF STANDARD CURVE

Results of a typical standard run with optical density readings at 450 nm shown in the Y axis against β -hCG concentrations shown in the X axis. This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each user should obtain his or her own data and standard curve.

β -hCG(ng/ml)	Absorbance (450nm)
0	0.061
2.5	0.296
5.0	0.498
10.0	0.929
25.0	1.711
50.0	2.613



STANDARDIZATION

For intact hCG, 1 ng is approximately equivalent to 15 mIU (WHO, 1st IRP 75/537). For free β -hCG subunit, since there is no WHO standardization, we tested the free β -hCG against Atlas hCG ELISA kit, and found 1 ng of free β -hCG equals to 0.1 mIU in terms of hCG immunological activity.

EXPECTED VALUES

The following information is cited from reference #12:

1. hCG and Free β -hCG Subunit Levels in Normal Pregnancy

A logarithmic increase in the serum concentration of hCG was observed from 5-8 weeks of gestation (2,600 ng/ml to 33,000 ng/ml) as defined by last menstrual period; thereafter, hCG values decreased. Similarly, free β -hCG levels increased rapidly to reach maximum levels (~60 ng/ml) at 8-9 weeks of pregnancy, followed by a gradual decline during the next 11-12 weeks of gestation.

At 5 weeks of gestation, the ratio of free β -hCG to intact hCG is approximately 1.0 % (w/w). Thereafter, this ratio remains remarkably constant over 22 weeks of gestation (~ 0.5 % w/w).

2. hCG and Free Subunits Levels in Gestational Choriocarcinoma

Free α and free β -subunits and hCG levels were measured in

five patients with untreated gestational choriocarcinoma. The concentrations in serum are shown in the following table:

Patient Number	hCG (ng/ml)	α -hCG (ng/ml)	β -hCG (ng/ml)
1	210,000	112	8,000
2	22,195	20	1,300
3	6,840	1	232
4	36,000	44	3,900
5	4,200	2	350

The levels of free α -hCG were low, ranging from 1-112 ng/ml, whereas hCG levels ranged from 4,200 to 210,000 ng/ml (1 ng - 15 mIU). In contrast, free β -hCG concentrations were found to be markedly elevated in choriocarcinoma.

3. Ectopic Production of hCG and Free Subunits by Nontrophoblastic Tumors

The following table shows results obtained in various tumors and healthy and benign disease controls.

Measurement of hCG, α -hCG, and β -hCG serum levels in nontrophoblastic tumors, benign disease, and healthy controls:

Tumor type	No. of samples	hCG (ng/ml)	α -hCG (ng/ml)	R-hCG (ng/ml)
Cervix	20	0	(1.6) ^a	1 (0.65)
Corpus uterus	20	0	0	0
Gastric	20	0	0	1 (1.5)
Pancreatic	20	0	(16.0)	2 (0.8, 3.1)
Colon	20	0	0	0
Lung	20	0	(90.0)	1 (0.7)
Ovarian	20	0	(1.8)	0
Prostate	20	0	(1.6)	0
Other digestive tract tumor	18	0	0	0
Total [%]	178	0	5 [3]	5 [3]
Benign disease controls	61	0	(1.6)	0
Healthy controls	50	0	0	0
Total [%]	111	0	1 [1]	0

^a The number in parentheses represents the measured value in ng/ml.

The cut-off values for positive results are 1.5 ng/ml for hCG and α -hCG and 0.4 ng/ml for β -hCG.

When compared with healthy control values, all nontrophoblastic cancer patients had hCG concentration within the normal range (~ 0.9 ng/ml). Free subunits were elevated in 10 of 178 patients. It is noteworthy that α -hCG levels in two patients (pancreatic and lung tumors) were relatively high (16 and 90 ng/ml, respectively), whereas the maximum concentration of free β -hCG was only 3.1 ng/ml (pancreatic tumor).

4. Free β -hCG, the maternal serum marker for Down Syndrome screening

The following information is cited from reference #6:

- Down Syndrome, or Trisomy 21, is the most common serious autosomal chromosome aberration in which affected individuals survive beyond infancy.
- Down Syndrome is characterized by mental retardation, a high risk of malformations of the heart, digestive system, eyes and ears,

and the development of pathological changes in the brain.

The following information is cited from reference #11:

- As shown in the following table, a significant increase in the level of free β -hCG was observed in trisomy 21 cases as compared with controls ($p < 0.0001$ using the Wilcoxon test).

Median maternal serum free β -hCG levels

Weeks' gestation	Control (ng/ml)	Trisomy 21 (ng/ml)
14-16	16.3	34.7
17-18	10.9	19.9

- Detection efficiencies for free β -hCG alone and in combination with AFP are shown in the following table.

Trisomy 21 screening efficiency with free β -hCG and in combination with AFP at different gestational age ranges at 5% false-positive rate

Gestational age range (wk)	No. of controls	No. of cases of Trisomy 21	Detection efficiency of Free β -hCG (%)	Detection efficiency of AFP and free β -hCG (%)
< 17	240	15	66.7	80.0
> 17	210	14	50.0	64.3
14-22	450	29	58.6	72.4

Maximal detection efficiency was achieved by using maternal serum AFP and free β -hCG at 14-16 weeks. It is effective to include a combination of maternal serum AFP and free β -hCG in a screening protocol for trisomy 21 to achieve the high detection efficiency with low false-positive rates.

SENSITIVITY

The minimum detectable concentration of this β -hCG in this assay is estimated to be 0.25 ng/ml.

Limitations of the Procedure

- Reliable and reproducible results will be obtained when the assay procedure is carried out with a complete understanding of the package insert instructions and will adhere to good laboratory practice.
- The wash procedure is critical. Insufficient washing will result in poor precision and falsely elevated absorbance readings.
- Serum samples demonstrating gross lipemia, gross hemolysis, or turbidity should not be used with this test.
- The results obtained from the use of this kit should be used only as an adjunct to other diagnostic procedures and information available to the physician.

REFERENCES

- Engall, E., Methods in Enzymology, Volume 70, Van Vunakis, H. and Langone, J. J. (eds.), Academic Press, New York, 419-29 (1980).
- Uotila, M., Ruoslahti, E. and Engvall, E., J. Immunol. Methods, 42, 11-15 (1981).
- Brizot ML, Jauniaux E, Mckie AT, Farzaneh F, and Nicolaides KH. Hum Reprod 1995; 10: 2506-9

- Forest JC, Masse J, Rousseau F, Moutquin JM, Brideau NA, and Belanger M. Clin Biochem 1995; 28: 443-9
- Breimer L. Ann Clin Biochem 1995; 32: 233
- Loncar K, Barnabei VM, and Larsen JW Jr. Obstet Gynecol Surv 1995; 50: 316-20
- Densem J, and Wald NJ. Prenat Diagn 1995; 15: 94-5
- Ozturk M, Berkowitz R, Goldstein D, Bellet D, Wands JR. Am J Obstet Gynecol 1988; 158:193-8
- Wald NJ, Cuckle HS, Densem JW, et al. Br. Med J 1988; 297:883-7
- Hay DL. Br. J Obstet Gynaecol 1988; 95:1268-75
- Macri JN, et al. Am J Obstet Gynecol 1990; 163:1248-53
- Ozturk M et al. Endocrinology 1987; 120:549-58
- Cole LA, et al. Endocrinology 1983; 113:1176-78
- Gaspard UJ et al. Clin Endocrinol (OXF) 1980;13:319-29

Atlas Medical
William James House, Cowley Rd.
Cambridge, CB4 0WX
Tel: ++44 (0) 1223 858 910
Fax: ++44 (0) 1223 858 524
United Kingdom

PPI163A01
Revision A (20.02.2005)